Here’s a good example of the advantage of being early in biotech.
Before Moderna went public in 2018, it had no products on the market.
It was a microcap focused on the once-obscure niche of messenger RNA products…
And its share price stayed well below $30 for its first year of trading.
But once news leaked that its COVID vaccine would win FDA approval in Dec. 2020…
The stock went on a tear from $29 in March 2020 to $451 in September 2021.
Of course, the rally was driven by worldwide COVID-19 vaccination.
And since the world has moved on, it’s understandable the stock now sits at $118.
STILL, the one thing you’ll notice is the clear advantage of being early.
If you bought at $50, you didn’t profit as much as the guy who bought at $29.
The trick is knowing the best time to get in and out for maximum returns and… A proven way to get your timing right is to follow the paper trail of insiders.